Alluvi, known as BI 4744, represents a significant breakthrough in obesity care. This dual agonist targeting both GLP-1 and GIP receptors demonstrates compelling results in patient studies, potentially surpassing https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/